Recent FDA announcements, draft guidance and NIH investment signal an accelerating shift toward integrated, human-relevant evidence that combines advanced in vitro systems, computational modeling and AI-enabled approaches.

At Concept Life Sciences, we help biopharmaceutical companies build integrated NAMs strategies that generate decision-ready data across discovery and preclinical development. Our team combines translational biology, advanced disease models, biomarker science, toxicology, bioanalysis, computational approaches and regulatory expertise into a single scientific strategy.

‍

Why new approach methodologies matter

Traditional drug development can suffer from poor translation between animal models and human biology. NAMs help overcome these limitations by generating data that is:

• More predictive of human outcomes.
• Mechanistically informative.
• Earlier in development.
• Better aligned with evolving regulatory expectations.
• More efficient for program decision making.

The objective is not simply replacing animal studies. It’s enabling you to make better scientific decisions earlier.

Accelerating the adoption of NAMs

A major regulatory shift is underway

Recent FDA initiatives represent one of the biggest changes to preclinical drug development in decades. These include:

• Draft guidance encouraging the use of validated alternatives to animal testing where scientifically appropriate.
• Greater acceptance of integrated evidence packages.
• Increased investment with NIH into advanced human-relevant technologies.
• Growing recognition of computational models, AI and in silico prediction.
• Continued expansion of program such as ISTAND supporting innovative development tools.

For developers, this creates an opportunity to generate more predictive evidence while potentially reducing development timelines, costs and late-stage risk.

Beyond in vitro: The future of NAMs is integrated science

Many organizations still think of NAMs as simply replacing animal studies with cell-based assays. The future is considerably broader. Modern NAMs integrate multiple evidence streams including:

Computational Approaches for Next-Generation Drug Discovery

‍In silico modeling and CADD

One of the fastest-growing areas of regulatory interest is the application of computational science alongside laboratory based NAMs.

Recent FDA communications highlight the importance of computational modeling and AI-supported approaches as complementary evidence for nonclinical decision making. These approaches can strengthen the overall weight of evidence when combined with experimental data. Concept Life Sciences supports computationally informed drug discovery through:

• Computer-Aided Drug Design (CADD)
• Structure-based drug design
• Ligand optimization
• Molecular modeling
• Predictive ADME modeling
• Bioinformatics
• Mechanistic data interpretation
• Integrated translational biology

Rather than replacing laboratory studies, computational approaches help optimize experimental design, prioritize candidates and generate stronger mechanistic evidence.

Our integrated NAMs capabilities

Why work with Concept Life Sciences?

Many CROs now promote NAMs, but few can integrate every component required for a successful regulatory strategy.

Unlike providers that focus primarily on toxicology or individual technologies, Concept Life Sciences brings together expertise across biology, chemistry, ADME/DMPK, toxicology, bioanalysis and CMC to support programs from concept through to clinic.

What makes us different?

Applications

We support NAMs across:

• Immunology
• Inflammation
• Autoimmune disease
• Fibrosis
• Oncology
• Respiratory disease
• Dermatology
• Neuroscience
• Rare disease
• Cell and Gene Therapy
• Biologics
• Small molecules

Our Scientific Approach

INSERT IMAGE

‍

Featured Resources

NAMs and Regulatory Shifts Driving Safer, More Predictive Therapeutic Outcomes

The Future of Safer, More Predictive Drug Development – Insights on NAMs

The Medicine Maker - Why the Future of Drug Development Must Be Human

NAMs FAQs

Q: What are New Approach Methodologies (NAMs)?

A: NAMs are human-relevant scientific methods that combine advanced in vitro models, computational approaches, organoids, biomarkers and translational biology to improve prediction of drug safety and efficacy.

Q: Are NAMs replacing animal testing?

A: Not entirely. Regulatory agencies increasingly encourage scientifically justified alternatives where appropriate, often using integrated evidence from multiple NAMs technologies alongside traditional approaches.

Q: What is the FDA's position on NAMs?

A: The FDA has released draft guidance encouraging greater use of scientifically validated alternatives to animal testing and is investing alongside NIH in advancing human-relevant technologies, computational models and AI-enabled approaches.

Q: What is in silico modeling?

A: In silico methods use computer modeling, AI and computational biology to predict drug behavior, optimize candidates and support regulatory decision making.

Q: What is computer-aided drug design (CADD)?

CADD uses molecular modeling, structural biology and computational chemistry to identify and optimize drug candidates before laboratory testing, helping reduce development time and improve candidate selection.

Q: Can Concept Life Sciences design an integrated NAMs strategy?

A: Yes. We work with clients to combine translational biology, advanced in vitro models, biomarkers, toxicology, ADME/DMPK, bioinformatics and computational approaches into a tailored program aligned with scientific and regulatory objectives.